Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
about
The consensus-based approach for gene/enzyme replacement therapies and crystallization strategies: the case of human alanine-glyoxylate aminotransferaseA zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaSustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVIIGene therapy for haemophilia: a long and winding road.The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.
P2860
Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Catalytic domain modification ...... vels and vector doses in vivo.
@en
Catalytic domain modification ...... vels and vector doses in vivo.
@nl
type
label
Catalytic domain modification ...... vels and vector doses in vivo.
@en
Catalytic domain modification ...... vels and vector doses in vivo.
@nl
prefLabel
Catalytic domain modification ...... vels and vector doses in vivo.
@en
Catalytic domain modification ...... vels and vector doses in vivo.
@nl
P2093
P2860
P1433
P1476
Catalytic domain modification ...... evels and vector doses in vivo
@en
P2093
Armida Faella
Harre D Downey
Lacramioara Ivanciu
Paris Margaritis
Ralph M Bunte
Shangzhen Zhou
P2860
P304
P356
10.1182/BLOOD-2010-09-309732
P407
P577
2011-02-16T00:00:00Z